EUR 3.92
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 14.45 Million EUR | -17.64% |
2022 | 17.55 Million EUR | -2.94% |
2021 | 18.08 Million EUR | -3.37% |
2020 | 18.72 Million EUR | 52.08% |
2019 | 12.31 Million EUR | 4.35% |
2018 | 11.79 Million EUR | 18.25% |
2017 | 9.97 Million EUR | 54.9% |
2016 | 6.44 Million EUR | 5.62% |
2015 | 6.09 Million EUR | 16.59% |
2014 | 5.23 Million EUR | 12.63% |
2013 | 4.64 Million EUR | -18.53% |
2012 | 5.7 Million EUR | -1.31% |
2011 | 5.77 Million EUR | -15.47% |
2010 | 6.83 Million EUR | -6.98% |
2009 | 7.34 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q4 | 14.45 Million EUR | 0.0% |
2023 Q2 | 16.44 Million EUR | 0.0% |
2023 FY | 14.45 Million EUR | -17.64% |
2022 Q4 | 17.55 Million EUR | 0.0% |
2022 Q2 | 16.61 Million EUR | 0.0% |
2022 FY | 17.55 Million EUR | -2.94% |
2021 Q2 | 16.5 Million EUR | 0.0% |
2021 FY | 18.08 Million EUR | -3.37% |
2021 Q4 | 18.08 Million EUR | 0.0% |
2020 Q2 | 17.46 Million EUR | 0.0% |
2020 Q4 | 18.72 Million EUR | 0.0% |
2020 FY | 18.72 Million EUR | 52.08% |
2019 Q2 | 12.47 Million EUR | 0.0% |
2019 Q4 | 12.31 Million EUR | 0.0% |
2019 FY | 12.31 Million EUR | 4.35% |
2018 Q2 | 10.86 Million EUR | 0.0% |
2018 FY | 11.79 Million EUR | 18.25% |
2018 Q4 | 11.79 Million EUR | 0.0% |
2017 Q4 | 9.97 Million EUR | 0.0% |
2017 Q2 | 10.04 Million EUR | 0.0% |
2017 FY | 9.97 Million EUR | 54.9% |
2016 Q4 | 6.44 Million EUR | 0.0% |
2016 Q2 | 6.1 Million EUR | 0.0% |
2016 FY | 6.44 Million EUR | 5.62% |
2015 FY | 6.09 Million EUR | 16.59% |
2015 Q2 | 5.14 Million EUR | 0.0% |
2015 Q4 | 6.09 Million EUR | 0.0% |
2014 Q4 | 5.23 Million EUR | 0.0% |
2014 Q2 | 4.99 Million EUR | 0.0% |
2014 FY | 5.23 Million EUR | 12.63% |
2013 Q2 | 5.13 Million EUR | 0.0% |
2013 Q4 | 4.64 Million EUR | 0.0% |
2013 FY | 4.64 Million EUR | -18.53% |
2012 FY | 5.7 Million EUR | -1.31% |
2012 Q4 | 5.7 Million EUR | 0.0% |
2012 Q2 | 6.26 Million EUR | 0.0% |
2011 FY | 5.77 Million EUR | -15.47% |
2011 Q4 | 5.77 Million EUR | 0.0% |
2011 Q2 | 7.08 Million EUR | 0.0% |
2010 FY | 6.83 Million EUR | -6.98% |
2010 Q4 | 6.83 Million EUR | 0.0% |
2010 Q2 | 6.68 Million EUR | 0.0% |
2009 Q4 | 7.34 Million EUR | 0.0% |
2009 Q2 | 5.73 Million EUR | 0.0% |
2009 FY | 7.34 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | -109.194% |
ABIVAX Société Anonyme | 131.05 Million EUR | 88.967% |
Adocia SA | 31.87 Million EUR | 54.63% |
Aelis Farma SA | 13.08 Million EUR | -10.547% |
Biophytis S.A. | 15.84 Million EUR | 8.767% |
Advicenne S.A. | 24.37 Million EUR | 40.684% |
IntegraGen SA | 5.97 Million EUR | -141.806% |
Medesis Pharma S.A. | 6.42 Million EUR | -125.009% |
Neovacs S.A. | 3.71 Million EUR | -289.521% |
NFL Biosciences SA | 3.62 Million EUR | -299.359% |
Plant Advanced Technologies SA | 6.78 Million EUR | -113.193% |
Quantum Genomics Société Anonyme | 3.31 Million EUR | -336.829% |
Sensorion SA | 13.22 Million EUR | -9.316% |
Theranexus Société Anonyme | 5.01 Million EUR | -188.257% |
TME Pharma N.V. | 2.78 Million EUR | -419.193% |
Valbiotis SA | 13.7 Million EUR | -5.482% |
TheraVet SA | 1.48 Million EUR | -873.709% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | 29.356% |
argenx SE | 402.79 Million EUR | 96.41% |
BioSenic S.A. | 32.26 Million EUR | 55.184% |
Celyad Oncology SA | 9.97 Million EUR | -44.914% |
DBV Technologies S.A. | 38.74 Million USD | 62.681% |
Galapagos NV | 1.56 Billion EUR | 99.074% |
Genfit S.A. | 105.92 Million EUR | 86.349% |
GeNeuro SA | 20.13 Million EUR | 28.205% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -67.9% |
Innate Pharma S.A. | 132.29 Million EUR | 89.07% |
Inventiva S.A. | 101.59 Million EUR | 85.767% |
MaaT Pharma SA | 22.46 Million EUR | 35.635% |
MedinCell S.A. | 77.77 Million EUR | 81.407% |
Nanobiotix S.A. | 95.74 Million EUR | 84.897% |
Onward Medical N.V. | 25.69 Million EUR | 43.733% |
Oryzon Genomics S.A. | 25.12 Million EUR | 42.451% |
OSE Immunotherapeutics SA | 59.07 Million EUR | 75.525% |
Oxurion NV | 19.73 Million EUR | 26.735% |
Pharming Group N.V. | 228.28 Million EUR | 93.666% |
Poxel S.A. | 53.9 Million EUR | 73.174% |
GenSight Biologics S.A. | 34.72 Million EUR | 58.362% |
Transgene SA | 26.51 Million EUR | 45.471% |
Financière de Tubize SA | 123.65 Million EUR | 88.306% |
UCB SA | 6.56 Billion EUR | 99.78% |
Valneva SE | 341.14 Million EUR | 95.761% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | -218.001% |